Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45
Deutsche Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Hold Rating on GlaxoSmithKline: Balancing Promising Guidance With Existing Challenges
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
CFRA Initiates GlaxoSmithKline(GSK.US) With Hold Rating, Announces Target Price $40
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) Gets a Hold From UBS
GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
Barclays Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
UBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (GB:GSK), CSL (OtherCMXHF) and Opthea Limited (OtherCKDXF)
GlaxoSmithKline: Sell Rating Amidst Weak Vaccine Performance and Projected EPS Decline
GlaxoSmithKline (GSK) Receives a Hold From Jefferies
Kepler Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Bernstein Remains a Buy on GlaxoSmithKline (GSK)